Repository logo
 
Publication

Persistence with medical glaucoma therapy in newly diagnosed patients

2024-08Journal article Open access
Simple item page
dc.contributor.authorMenino, Joana
dc.contributor.authorCamacho, Pedro
dc.contributor.authorCoelho, André
dc.date.accessioned2024-08-28T11:14:48Z
dc.date.available2024-08-28T11:14:48Z
dc.date.issued2024-08
dc.descriptionThis project was partially supported by FCT/MCTES (UIDB/05608/2020 and UIDP/05608/2020).pt_PT
dc.description.abstractBackground: Monotherapy, age, and side effects are significant risk factors for the discontinuation of antiglaucoma therapy. Long-term therapy persistence is crucial for slowing disease progression and preventing irreversible blindness. Therefore, it is essential to identify patients at higher risk of discontinuation. In this study, we aimed to evaluate the real-world persistence of antiglaucoma therapy in patients diagnosed with glaucoma in the primary healthcare units of the Lisbon and Tagus Valley regions. Methods: We conducted a retrospective longitudinal study by collecting data from the prescription records of new antiglaucoma drug users diagnosed with glaucoma between 2012 and 2013 in the Primary Health Care Units of the Lisbon and Tagus Valley Region. These patients were followed over 3 years. Therapy persistence was measured as the proportion of patients remaining on any antiglaucoma drug, regardless of any modifications or switching of drugs over time. Persistence was assessed at three time points: the end of the first, second, and third years of the observation period. Results: A total of 2138 patients treated using new antiglaucoma drugs (867 [40.6%] male patients; 1271 [59.4%] female patients) were included in the study. Over the observation period, the overall persistence rate decreased from 91.9% (n = 1965) in the first year to 67.3% (n = 1439) in the third year. Older patients (≥ 65 years) showed higher persistence rates, although there was a decrease over the 3-year follow-up period (from 1481 [92.7%] to 1124 [70.4%]). Additionally, participants initially treated with monotherapy showed higher persistence rates, ranging from 92.4% (n = 1186) in the first year to 70.2% (n = 901) in the third year. Conclusions: The findings highlight the importance of patient follow-up over time, as almost one in three new antiglaucoma therapy users completely discontinued treatment, potentially risking disease progression. This could be mitigated with proper use of these drugs. Further studies should utilize recent health information systems to explore the impact of medication adherence and persistence on the functional and structural outcomes in patients with glaucoma.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMenino J, Camacho P, Coelho A. Persistence with medical glaucoma therapy in newly diagnosed patients. Med Hypothesis Discov Innov Ophthalmol. 2024;13(2):63-9.pt_PT
dc.identifier.doi10.51329/mehdiophthal1495pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/17631
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherInternational Virtual Ophthalmic Research Centerpt_PT
dc.relation.publisherversionhttps://mehdijournal.com/index.php/mehdiophthalmol/article/view/1175pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectOphthalmologypt_PT
dc.subjectGlaucomapt_PT
dc.subjectAnti-glaucoma therapypt_PT
dc.subjectDrug persistencept_PT
dc.subjectTherapy persistencept_PT
dc.subjectDrug discontinuationpt_PT
dc.subjectMedication non-adherencept_PT
dc.subjectUIDB/05608/2020pt_PT
dc.subjectUIDP/05608/2020pt_PT
dc.titlePersistence with medical glaucoma therapy in newly diagnosed patientspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage69pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage63pt_PT
oaire.citation.titleMedical Hypothesis Discovery and Innovation in Ophthalmologypt_PT
oaire.citation.volume13pt_PT
person.familyNameCamacho
person.familyNameFerreira Ramos Coelho
person.givenNamePedro
person.givenNameAndré Filipe
person.identifier.ciencia-id271F-B4E1-014E
person.identifier.ciencia-id291E-1AC6-86FA
person.identifier.orcid0000-0002-2986-5652
person.identifier.orcid0000-0003-1872-8131
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationc41e9c52-157e-4375-8005-b609cfc374e7
relation.isAuthorOfPublicatione00e9fd8-697d-4e70-acd3-e5a5169360ed
relation.isAuthorOfPublication.latestForDiscoverye00e9fd8-697d-4e70-acd3-e5a5169360ed

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Persistence with medical glaucoma therapy in newly diagnosed patients.pdf
Size:
1.25 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos